CRISPR Therapeutics (CRSP) News Today $42.94 +0.85 (+2.02%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$43.31 +0.37 (+0.86%) As of 06/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6% - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6% - Should You Buy?June 10 at 1:04 PM | marketbeat.comBrokers Issue Forecasts for CRSP FY2026 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of CRISPR Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per shareJune 10 at 9:17 AM | marketbeat.comCRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)June 9 at 6:31 PM | seekingalpha.comCRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last MonthJune 7, 2025 | finance.yahoo.comCRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)June 3, 2025 | seekingalpha.comThe Best Stocks to Invest $1,000 in Right NowJune 3, 2025 | fool.comGreen Alpha Advisors LLC Buys 32,732 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Green Alpha Advisors LLC grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 132.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 57,361 shares of the company's stock after purchasing an additionaJune 2, 2025 | marketbeat.comZacks Research Analysts Increase Earnings Estimates for CRSPJune 1, 2025 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Insider Naimish Patel Sells 3,932 SharesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) insider Naimish Patel sold 3,932 shares of the stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now owns 6,068 shares of the company's stock, valued at approximately $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.May 31, 2025 | marketbeat.comNaimish Patel Sells 3,932 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) StockMay 31, 2025 | insidertrades.comZacks Research Analysts Raise Earnings Estimates for CRSPCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research lifted their Q2 2025 earnings estimates for CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, May 27th. Zacks Research analyst R. Department now expects that the company will earn ($May 31, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Capital Market Strategies LLCCapital Market Strategies LLC boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 82.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,367 shares of the compMay 31, 2025 | marketbeat.comVoloridge Investment Management LLC Decreases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Voloridge Investment Management LLC trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 68.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,835 shares of theMay 30, 2025 | marketbeat.comCathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stockMay 29, 2025 | investing.comCRISPR Therapeutics to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 13,865 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund ownedMay 28, 2025 | marketbeat.comTwo Sigma Advisers LP Purchases 28,400 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Two Sigma Advisers LP grew its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 50.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,800 shares of the company's stock after acquiring an aMay 28, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of "Moderate Buy" by BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has received an average recommendation of "Moderate Buy" from the eighteen research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and tenMay 28, 2025 | marketbeat.comTwo Sigma Investments LP Boosts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)Two Sigma Investments LP raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 71.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 306,272 shares of the company's stock after buying an additional 127,May 26, 2025 | marketbeat.comMizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)May 24, 2025 | theglobeandmail.comLeerink Partnrs Issues Negative Estimate for CRSP EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for CRISPR Therapeutics in a research report issued on Monday, May 19th. Leerink Partnrs analyst M. Foroohar now anticipates that the company willMay 24, 2025 | marketbeat.comWilliam Blair Has Bearish Estimate for CRSP Q2 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - William Blair lowered their Q2 2025 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, May 20th. William Blair analyst S. Corwin now forecasts that the company will earn ($2.27) per share forMay 24, 2025 | marketbeat.comAmeriprise Financial Inc. Has $8.07 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Ameriprise Financial Inc. raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 205,173 shares of the company's stock aMay 24, 2025 | marketbeat.comCRISPR Therapeutics' (CRSP) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday.May 23, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Westwood Holdings Group Inc.Westwood Holdings Group Inc. boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 18.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,102 shares of the company's stock after purcMay 23, 2025 | marketbeat.comCRISPR Therapeutics' (CRSP) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Tuesday.May 22, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 21.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 79,967 shares of the company's stockMay 22, 2025 | marketbeat.comCRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot DrugMay 21, 2025 | insidermonkey.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Rafferty Asset Management LLCRafferty Asset Management LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 22.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 165,816 shares of the company's stock afMay 20, 2025 | marketbeat.comCRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?May 20, 2025 | fool.com5 Monster Stocks to Hold for the Next 10 YearsMay 20, 2025 | fool.comNorthern Trust Corp Increases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Northern Trust Corp increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 12.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 257,168 shares of the company's stock after buying an addiMay 20, 2025 | marketbeat.comCrispr Therapeutics to Partner With Sirius Therapeutics to Develop siRNA TherapiesMay 20, 2025 | marketwatch.comCRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA TherapiesMay 20, 2025 | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Announces Strategic Partnership with Sirius Therapeutics | CRSP ...May 19, 2025 | gurufocus.comCrispr Therapeutics AG Partners with Sirius on siRNA TechMay 19, 2025 | tipranks.comLazard Asset Management LLC Decreases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Lazard Asset Management LLC decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,023 shareMay 19, 2025 | marketbeat.comPrediction: This Beaten-Down Stock Could Double in The Next 5 YearsMay 18, 2025 | fool.comBank of America Corp DE Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Bank of America Corp DE boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 12.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,211,509 shares of the company's stock after buying an additiMay 17, 2025 | marketbeat.comCRSPR Stock Could Be Ready to Deliver on Its Massive PromiseCRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholdersMay 16, 2025 | marketbeat.comCresset Asset Management LLC Sells 12,037 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Cresset Asset Management LLC lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 44.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,042 shares of the company's stoMay 16, 2025 | marketbeat.comAre Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?May 15, 2025 | msn.comChardan Capital Issues Optimistic Forecast for CRSP EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Chardan Capital lifted their FY2025 EPS estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now forecasts thatMay 13, 2025 | marketbeat.comQ2 EPS Estimate for CRISPR Therapeutics Raised by AnalystCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst M. Kapoor now anticMay 13, 2025 | marketbeat.comCan Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?May 12, 2025 | fool.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $42.00 at BarclaysBarclays lowered their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday.May 11, 2025 | marketbeat.comQ2 EPS Forecast for CRISPR Therapeutics Lowered by AnalystCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Brookline Capital Management reduced their Q2 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a report issued on Tuesday, May 6th. Brookline Capital Management analyst L. Cann now forecMay 11, 2025 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for CRSP EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.45)May 11, 2025 | marketbeat.comWilliam Blair Expects Lower Earnings for CRISPR TherapeuticsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - William Blair decreased their Q2 2025 earnings per share estimates for shares of CRISPR Therapeutics in a report released on Wednesday, May 7th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.10May 11, 2025 | marketbeat.com3 Monster Stocks to Hold for the Next 10 YearsMay 10, 2025 | fool.com Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.920.71▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼611▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neurocrine Biosciences News Exelixis News Moderna News Qiagen News Bio-Techne News Revolution Medicines News Repligen News Halozyme Therapeutics News ADMA Biologics News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
